Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer (Q36504117)
Jump to navigation
Jump to search
scientific article published on 26 May 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer |
scientific article published on 26 May 2009 |
Statements
1 reference
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer (English)
1 reference
Mitch Dowsett
1 reference
Gerhardt Attard
1 reference
Alison H M Reid
1 reference
Roger A'Hern
1 reference
Christopher Parker
1 reference
Nikhil Babu Oommen
1 reference
Elizabeth Folkerd
1 reference
Christina Messiou
1 reference
L Rhoda Molife
1 reference
Gal Maier
1 reference
Emilda Thompson
1 reference
David Olmos
1 reference
Rajesh Sinha
1 reference
Gloria Lee
1 reference
Stan B Kaye
1 reference
David Dearnaley
1 reference
Thian Kheoh
1 reference
Arturo Molina
1 reference
Johann S de Bono
1 reference
26 May 2009
1 reference
1 reference
3742-3748
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference